Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Lumos Pharma (LUMO) has shared an update.
At Lumos Pharma’s 2024 Annual Meeting, shareholders elected directors Chad A. Johnson and Lota S. Zoth, approved the executive compensation on an advisory basis, decided on annual advisory votes for future executive compensation, and ratified KPMG, LLP as the independent auditor for the fiscal year. The company also announced new analyses from the Phase 2 OraGrowtH212 trial at ENDO 2024, details of which were shared in a press release and an updated corporate slide deck. These updates highlight the company’s ongoing commitment to transparency and shareholder engagement in its governance and operational progress.
See more insights into LUMO stock on TipRanks’ Stock Analysis page.
